The goal of this commentary is to provide recent pharmacy school graduates and student pharmacists completing APPEs the essential background for correct vancomycin therapeutic drug monitoring (TDM) in the inpatient setting.
DanielsonJBesinqueKHClarkeC, et al.Essential elements for core required advanced pharmacy practice experiences. Am J Pharm Educ. 2019;83(4):6865. doi:10.5688/ajpe6865.
LevineDP. Vancomycin: A history. Clin Infect Dis. 2006;42(Suppl 1):S5-S12. doi:10.1086/491709.
4.
RybakMJLomaestroBMRotschaferJC, et al.Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases society of America, the American society of health-system pharmacists, and the society of infectious diseases pharmacists [published correction appears in Clin Infect Dis. 2009 Nov 1;49(9):1465]. Clin Infect Dis. 2009;49(3):325-327. doi:10.1086/600877.
5.
RybakMJLeJLodiseTP, et al.Therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections: A revised consensus guideline and review of the American society of health-system pharmacists, the infectious diseases society by America, the pediatric infectious diseases society, and the society of infectious diseases pharmacists. Am J Health-Syst Pharm. 2020;77:835-864. doi:10.1093/ajhp/zxaa036.
6.
SouthwoodRLFlemingVHAmerican Society of Health-System Pharmacists, et al.Half-life, elimination rate, and AUC. Concepts in Clinical Pharmacokinetics. 7th edition. ASHP; 2018.
7.
LodiseTPScheetzMCarrenoJJChambersHFowlerVJrHollandTL. Associations between vancomycin exposure and acute kidney injury within the recommended area under the curve therapeutic exposure range among patients with methicillin-resistant staphylococcus aureus bloodstream infections. Open Forum Infect Dis. 2022;9(2):ofab651. doi:10.1093/ofid/ofab651.
8.
FinchNAZasowskiEJMurrayKP, et al. A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity. Antimicrob Agents Chemother2017;61(12):e01293-17. doi:10.1128/AAC.01293-17.
9.
AljefriDMAvedissianSNRhodesNJPostelnickMJNguyenKScheetzMH. Vancomycin area under the curve and acute kidney injury: A meta-analysis. Clin Infect Dis. 2019;69(11):1881-1887. doi:10.1093/cid/ciz051.
10.
NeelyMNKatoLYounG, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother2018;62(2):e02042-17. doi:10.1128/AAC.02042-17.
11.
DrennanPGBeggEJGardinerSJKirkpatrickCMJChambersST. The dosing and monitoring of vancomycin: What is the best way forward?Int J Antimicrob Agents. 2019;53(4):401-407. doi:10.1016/j.ijantimicag.2018.12.014.
12.
HoDArquietteJKimMK. Bayesian-estimated vancomycin area under the curve using a single trough concentration vs 2 concentrations. Am J Health Syst Pharm. 2021;78(18):1663-1664. doi:10.1093/ajhp/zxab233.
13.
NeelyMNYounGJonesB, et al.Are vancomycin trough concentrations adequate for optimal dosing?Antimicrob Agents Chemother. 2014;58(1):309-316. doi:10.1128/AAC.01653-13.
14.
KufelWDSeaburyRWMogleBTBeccariMVProbstLASteeleJM. Readiness to implement vancomycin monitoring based on area under the concentration-time curve: A cross-sectional survey of a national health consortium. Am J Health Syst Pharm. 2019;76(12):889-894. doi:10.1093/ajhp/zxz070.
